about
Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell lineA comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferationUnacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor.Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.The toxicology of chemokine inhibition.Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomasAdamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1Evolving concepts in the quest for advanced therapeutic analogues of somatostatin.In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parametersIn1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.PYY3-36 as an anti-obesity drug target.Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?Actions of Agonists and Antagonists of the ghrelin/GHS-R Pathway on GH Secretion, Appetite, and cFos Activity.Novel chimeric somatostatin analogs: facts and perspectives.Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.Constitutive somatostatin receptor activity determines tonic pituitary cell response.Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.Somatostatin analogs for the treatment of neuroendocrine tumors.Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors.Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.Regulation of prostate cancer cell proliferation by somatostatin receptor activation.Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
P50
Q28204929-A4B49C59-94EB-4F95-AE3B-7DE5A9EFF138Q28568444-8E95D41A-D8B7-4B23-863D-BD6B2582DDCBQ30968720-07553672-2325-4A83-B498-8958DEA74E7BQ33631389-BD1DFB65-5ACC-4F38-BDA9-F8148DFBFC33Q33802142-37303098-4555-4214-8A88-9503AF143BABQ34002856-0B81AAB5-E871-4218-A83A-B02EEB4A6EB3Q34453072-1AB8B43B-4A0E-4EE9-8121-B2C29FDCE41DQ35228970-497C219C-9FA1-43BB-B9F1-30D49C330051Q35231710-D7FFE601-6761-4803-9F4C-75BB7AA40DAAQ35743374-E4DD44A5-6D32-43D6-B7A8-633A107D4772Q36260604-05D7B408-A75B-4DE2-96B1-E2E47C566FBFQ36291593-7A6DB4ED-C9F1-4D8A-8F07-F57A9D340180Q36295641-22C78130-F7E9-429B-AA8F-613A44D6E3EEQ36434907-4DE7EDCF-6C66-407D-AAB4-F57816A2B691Q36615933-7DCDC182-21CD-46F6-BF67-310D22EB6378Q36693391-29D66144-AD9B-49B9-89D2-C2B3168AA3B5Q36782654-38862B35-81E2-4DBA-8E68-065FC488BA20Q36782668-59719BD0-47A2-400F-992C-C2DC81536C5EQ36916282-8D95A713-892A-4A6D-AA03-6F0D804971A0Q37302367-C6B7EC2E-FE13-44CD-B342-BC8F30ABD978Q37352148-8BBC6992-1FC6-4C71-864B-E4F299F58880Q37371469-02BBA993-45A3-415A-8B39-24CAE6EC35C5Q37499468-8EB9C8FC-F2EA-4055-9BF9-1CE29FF97714Q37633385-ABA52051-77A5-4CAD-833B-8BEF6A8AAF3EQ37644995-93AD4ACD-3BE5-4EC4-BFE2-86E6445FB274Q37849210-DCFD02E4-5FDA-480D-A7FC-0CF99402AEA2Q37944468-280279F5-B166-4BD4-AE55-73353E713A12Q38327230-3DC9E1CF-8B87-4172-BF56-3721D876DAA6Q39065274-9FAD0EEF-26AC-4C7E-9C57-1C138502F938Q39135618-699857EF-0F40-4879-A281-AF4463357A2DQ39650818-254A84BD-A4BD-4B83-A524-1495348FC889Q39702137-5C29A4AA-1170-45CD-873E-F4F2554748ADQ39771837-1E49EC02-5891-4227-9795-321A961397E9Q39837640-5E401430-3FC1-44DD-A32E-DA7FB9B64005Q39942651-8962E060-1E1F-49BE-9399-017B114502E6Q40111970-E4378E08-8CBD-4853-B238-3978A3E4E3E2Q40294769-5E626B7D-3D00-4C7E-B834-63AC73E214F7Q40298829-FCF08EC2-1494-46B2-836C-A30B57CB1984Q40392872-F0CEB3E9-2C54-41DC-8072-478A6440B388Q40509222-75289B75-0FE0-4850-BC61-7919154E0913
P50
description
researcher
@en
wetenschapper
@nl
name
Culler MD
@nl
Michael D. Culler
@en
type
label
Culler MD
@nl
Michael D. Culler
@en
altLabel
Culler MD
@en
prefLabel
Culler MD
@nl
Michael D. Culler
@en
P106
P31
P496
0000-0001-5168-8739